Table I.

Changes in the sensitivity of RYR2 to be opened by [Ca²⁺]_i

A—Increase in RYR2 sensitivity	B—Decrease in RYR2 sensitivity
Increased [Ca2+]SR	Decreased [Ca2+]SR
(Lukyanenko et al., 1996; Györke and Györke, 1998; Györke et al., 2002)	(Lukyanenko et al., 1996; Györke and Györke, 1998; Györke et al., 2002)
RYR2 phosphorylation at PKA or CaMKII sites	Calstabin2 (FKBP 12.6) binding
(Valdivia et al., 1995; Li et al., 1998; Marx et al., 2000)	(Marx et al., 2000; Wehrens et al., 2003)
Caffeine	Tetracaine
(Rousseau and Meissner, 1989; O’Neill and Eisner, 1990; Venetucci et al., 2007)	(Xu et al., 1993; Overend et al., 1997)
RYR2 oxidation (ROS)	Anti-oxidation
(Hidalgo et al., 2002; Terentyev et al., 2008)	(Hidalgo et al., 2002; Terentyev et al., 2008)
RYR2 CPVT mutations
(Marks et al., 2002; Wehrens et al., 2003)
Calsequestrin mutations
(Postma et al., 2002; Eldar et al., 2003; di Barletta et al., 2006; Knollmann et al., 2006)
Triadin
(Valdivia et al., 1995; Li et al., 1998; Marx et al., 2000; Györke and Terentyev, 2008; Chopra et al., 2009)
RYR2 nitrosylation
(Xu et al., 1998; Sun et al., 2008; Bellinger et al., 2009)